May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Intravitreal Injection of Bevacizumab for Persistent Diabetic Macular Edema After Vitrectomy
Author Affiliations & Notes
  • Y. Okamoto
    Ophthalmology, Univ of Tsukuba Inst of Clinical Medicine, Tsukuba, Japan
  • F. Okamoto
    Ophthalmology, Univ of Tsukuba Inst of Clinical Medicine, Tsukuba, Japan
  • T. Hiraoka
    Ophthalmology, Univ of Tsukuba Inst of Clinical Medicine, Tsukuba, Japan
  • T. Oshika
    Ophthalmology, Univ of Tsukuba Inst of Clinical Medicine, Tsukuba, Japan
  • Footnotes
    Commercial Relationships  Y. Okamoto, None; F. Okamoto, None; T. Hiraoka, None; T. Oshika, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 4474. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y. Okamoto, F. Okamoto, T. Hiraoka, T. Oshika; Intravitreal Injection of Bevacizumab for Persistent Diabetic Macular Edema After Vitrectomy. Invest. Ophthalmol. Vis. Sci. 2008;49(13):4474. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To investigate the efficacy of intravitreal injection of bevacizumab for persistent diabetic macular edema after vitreous surgery.

Methods: : Sixteen eyes of 16 patients (52 to 75 years old) were studied. A 1.25 mg of bevacizumab was injected intravitreally, and visual function and vision-related quality of life were evaluated before and 1 and 3 months after injection. We examined logMAR best corrected visual acuity (BCVA), letter contrast sensitivity with CSV-1000LV (Vector Vision), central retinal thickness using optical coherence tomography (Stratus OCT 3000, Carl Zeiss), and vision-related quality of life with the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25).

Results: : At 1 month after injection, statistically significant improvements were observed in central retinal thickness (p < 0.05) and letter contrast sensitivity (p < 0.05), whereas logMAR BCVA (p = 0.41) and VFQ-25 composite score (p = 0.29) did not improve significantly. At 3 months after injection, significant improvements were not observed in logMAR BCVA (p = 0.17), letter contrast sensitivity (p = 0.22), central retinal thickness (p = 0.40), and VFQ-25 composite score (p = 0.78).

Conclusions: : The intravitreal injection of bevacizumab for persistent diabetic macular edema after vitreous surgery temporarily improved central retinal thickness and letter contrast sensitivity, but did not improve visual acuity and vision-related quality of life.

Keywords: quality of life • diabetic retinopathy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×